Navigation Links
YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB PRESENTATIONS TO BE MADE AT THE 100TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH AND EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY
Date:3/13/2009

ther approaches using fentanyl because patients can individually control the analgesia required for their differing intensities of pain. AeroLEF met all endpoints in a randomized Phase II trial and is currently being prepared for late-stage development internationally.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that nimotuzumab will continue to demonstrate a competitive safety profile in ongoing and future clinical trials; that AeroLEF(R) will continue to generate positive efficacy and safety data in future clinical trials; and that YM and its various partners will complete their respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sangamo BioSciences Announces Presentations at Two Upcoming Investor Conferences
2. Hana Biosciences Announces New Positive Interim Efficacy Results in Pivotal rALLy Clinical Trial of Marqibo in Acute Lymphoblastic Leukemia
3. Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound
4. Cardio3 BioSciences Raises EUR13.7 Million in Series B Fundraising and Grant Funding
5. YM BioSciences Announces Milestone Payment For Approval Of Nimotuzumab In The Philippines And Indonesia
6. Sangamo BioSciences Provides Update on Companys 2008 Progress and 2009 Objectives
7. Chipscreen Biosciences and HUYA Bioscience Intl Announce Promising Preclincial and Phase I Solid Tumor/Lymphoma Data for Chidamide/HBI-8000, New HDAC Inhibitor for Cancer
8. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
9. Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting
10. Epiphany Biosciences to Continue Phase 2 Shingles Study After Interim Analysis; Plans Follow-On Clinical Trial Studying Post-Herpetic Neuralgia (PHN)
11. Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at American College of Gastroenterology Annual Scientific Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... S.C. , Sept. 18, 2014   3D Systems ... of the Simbionix RobotiX Mentor™ , a new robotic ... for the first time at the ERUS exhibition in ... 19 (booth #7). Robotic-assisted minimally invasive surgery represents ... demand means the needs for training for robotic surgery has ...
(Date:9/18/2014)... MELBOURNE, Australia , Sept. 18, 2014 ... appointments of Dr. Ashraf Hanna , M.D., Ph.D., ... its Board of Directors. Dr. Hanna is the Vice ... and Chief Financial Officer for the Genentech Foundation, while ... Global Head of Business Development and Licensing for Roche ...
(Date:9/18/2014)... Mass. , Sept. 18, 2014  Spring ... novel therapeutics for the treatment of RNA viruses, ... Institutes of Health (NIH) for animal testing of ... viral pathogens, classified as "Special Pathogens," against which ... 9200, derived from Spring Bank,s proprietary ...
Breaking Medicine Technology:3D Systems Introduces New Simbionix Robotics Training Platform 23D Systems Introduces New Simbionix Robotics Training Platform 3Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 2Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 3Spring Bank Pharmaceuticals Announces NIH Collaboration for Testing of SB 9200 Against Multiple Viral Pathogens 2
... BRUNSWICK, N.J., Aug. 10, 2011 Savient Pharmaceuticals, Inc. (Nasdaq: ... Chief Executive Officer and President of Savient will present at ... Tuesday, August 16, 2011, at 4:10 p.m. Eastern Time.  The ... New York, NY. A live webcast of ...
... 10, 2011 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) ... and development outsourcing company serving the pharmaceutical, biotechnology, and medical ... today announced its financial results for the second quarter of ... Quarterly Net Revenues Exceeded $100 Million for the First Time ...
Cached Medicine Technology:WuXi PharmaTech Announces Second Quarter 2011 Results 2WuXi PharmaTech Announces Second Quarter 2011 Results 3WuXi PharmaTech Announces Second Quarter 2011 Results 4WuXi PharmaTech Announces Second Quarter 2011 Results 5WuXi PharmaTech Announces Second Quarter 2011 Results 6WuXi PharmaTech Announces Second Quarter 2011 Results 7WuXi PharmaTech Announces Second Quarter 2011 Results 8WuXi PharmaTech Announces Second Quarter 2011 Results 9WuXi PharmaTech Announces Second Quarter 2011 Results 10WuXi PharmaTech Announces Second Quarter 2011 Results 11WuXi PharmaTech Announces Second Quarter 2011 Results 12WuXi PharmaTech Announces Second Quarter 2011 Results 13WuXi PharmaTech Announces Second Quarter 2011 Results 14WuXi PharmaTech Announces Second Quarter 2011 Results 15WuXi PharmaTech Announces Second Quarter 2011 Results 16WuXi PharmaTech Announces Second Quarter 2011 Results 17
(Date:9/18/2014)... 18, 2014 Throughout their lives, sisters ... other on, celebrate their achievements and accomplishments together, and ... and joy. , Joanie’s Sisters in Support, a support ... joined together by their battles against breast and ovarian ... which was organized in June, meets once a month ...
(Date:9/18/2014)... HealthDay Reporter THURSDAY, Sept. 18, 2014 (HealthDay ... therapy effectively treats normally sagging levels of the hormone in ... panel said Wednesday. The panel, from two key FDA ... drugs and require drug makers to conduct tests assessing the ... Bloomberg News . "The whole idea is to try ...
(Date:9/18/2014)... PLAINS, NY, SEPT. 18, 2014 -- Only about half ... shot each season, leaving thousands of moms-to-be and their babies ... a flu shot should be a routine part of prenatal ... officer. "Health care providers should offer their pregnant patients a ... should ask for it." , A report by the U.S. ...
(Date:9/18/2014)... 2014) -- Two independent groups of researchers led ... of Kentucky, and Charles Lowenstein, MD, of the ... the role that a gene called STXBP5 plays ... to Whiteheart, previous genome-wide association studies (GWAS) identified ... regulates a protein called Von Willebrand factor (VWF). ...
(Date:9/18/2014)... is available in German . ... strategy not to fight a pathogen tooth and nail, but rather ... One key feature of tolerance is that the disease only progresses ... carries a high pathogen load. , Roland Regoes, a senior scientist ... approach to HIV. He set about investigating whether there are infected ...
Breaking Medicine News(10 mins):Health News:Artist’s Cancer Jewelry to Benefit Joanie’s Sisters 2Health News:Artist’s Cancer Jewelry to Benefit Joanie’s Sisters 3Health News:FDA Panel: Limit Testosterone Drug Use 2Health News:FDA Panel: Limit Testosterone Drug Use 3Health News:FDA Panel: Limit Testosterone Drug Use 4Health News:Flu vaccine for expectant moms a top priority 2Health News:University of Kentucky research explores STXBP5 gene and its role in blood clotting 2Health News:Withdrawal from the evolutionary race 2Health News:Withdrawal from the evolutionary race 3
... ... in Christ for A Day of Breast Health Awareness, Education and Screenings , ... Philadelphia, Pa. (Vocus) October 2, 2009 -- ... with Praise is The Cure and the Health Ministry Program will have a day-long celebration ...
... ... with chronic sinusitis and recurring sinus infections. When antibiotics fail they are left with little ... ... SinusWars LLC has been treating sinus related conditions for years and has noticed an increase ...
... "Profile America" feature from the U.S. Census Bureau: , (Logo: ... 2: FIRST GYM INSTRUCTORS , Profile America ... staying fit. Often, they have exercise equipment at home, ... But most people interested in fitness plan their busy ...
... has discovered a new way to classify stomach cancers, ... toward designing more effective treatments and improving long-term survival. ... and represents the second leading cause of cancer deaths ... from patients in Singapore, Australia and the United Kingdom ...
... 1 Two interactive computer tools released today by ... emergency planners and responders select and run alternate care ... a surge in seriously ill patients requiring acute care ... alternate care sites. , Alternate care facilities ...
... ... of hydrolysates, the performance of FBS and the consistency of a defined media. , ... Fort Collins, CO (PRWEB) October 4, ... hamster ovaries) cell line enhancement called Zap-CHO . Zap-CHO is designed to deliver superior ...
Cached Medicine News:Health News:More than 500 Breast Cancer Survivors and Community Supporters to Attend Annual 'Praise is The Cure' Event 2Health News:SinusWars LLC Launches a Successful and All Natural Alternative to Antibiotics in the Fight to Treat Chronic Sinusitis 2Health News:Duke/Singapore scientists find new way to classify gastric cancers 2Health News:New Tools Help Emergency Planners Select Alternate Care Facilities and Transfer Patients During Disasters 2Health News:InVitria Launches Zap-CHO to Enhance CHO Cell Culture Performance 2Health News:InVitria Launches Zap-CHO to Enhance CHO Cell Culture Performance 3
10 L, Racked, 96 tips/rack Extended length pipette tips recommended for 5 and 10 L pipettes....
This 10 L tip was designed for the Pipetman P-2 and P-10. Its MicroPoint design and 2 ul reference mark make it ideal for low volume pipetting....
Designed to fit the Brinkmann Tranferpette and Treff Multi-Channel 300 L Pipettors, this tip provides extra space for repeat pipetting....
... Diagnostics West Nile Virus IgG DxSelect ... to West Nile virus in human,serum. ... West Nile Virus,IgM Capture DxSelect, the ... symptoms of meningioencephalitis, as an aid ...
Medicine Products: